|
The document discusses the submission of a Letter of Intent (LOI) by 3M to the EPA regarding PFOA, with instructions for verifying and processing the document to replace certain pages before it is officially docketed.
|
2008 |
AR226-3820
|
jyyMkO6EVXed0d2MELGRBzdr9 |
8 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, supplementing previous submissions regarding sulfonate and carboxylate-based fluorochemicals, including PFOA and PFOS, highlighting ongoing safety assessments and treatment protocols.
|
2008 |
AR226-3821
|
qaa7yy6o4OEe4M76pEb3xXo0n |
1 |
|
3M notified the EPA of a completed five-day repeat dose oral toxicity study on a fluorinated surfactant salt, revealing that all six female rats treated with 288 mg/kg/day died after four to five doses, while no male rats in the same group experienced mortality.
|
2008 |
AR226-3823
|
aJO944VgVyvyMznvDdv2XRZkR |
1 |
|
The document discusses 3M's assertion of confidentiality regarding certain business information related to a chemical substance they manufacture, indicating that the claim is intended to be indefinite to maintain competitive advantage.
|
2008 |
AR226-3824
|
5b7zr8re0bQYYNvzzj1Lmdm25 |
4 |
|
This document is a submission to the TSCA 8(e)/FYI Database by Robert A. Bilott, providing information regarding PFOA/PFOS, including C-8 Science Panel Status Reports and a study on health effects among community residents exposed to perfluorooctanoate.
|
2008 |
AR226-3825
|
5D7j6w3q3y8dNjN5X9XyVRw3V |
1 |
|
The document outlines the C8 Science Panel's submission of three status reports to the Wood County Court regarding health studies on PFOA and PFOS exposure in a community near a chemical plant, highlighting associations with cholesterol, diabetes, and other health measures.
|
2008 |
AR226-3826
|
6RwJYRkjJjEoGrYZaMeDaYQZR |
14 |
|
This study evaluates self-reported health effects among residents exposed to perfluorooctanoate (PFOA) in drinking water, finding statistically significant higher prevalence rates of serious health issues such as angina, myocardial infarction, and stroke, suggesting a potential link to PFOA exposure.
|
2008 |
AR226-3827
|
G5XGrBzOMpNQaj9waJKN0MJJr |
15 |
|
This document from 3M, dated September 17, 2008, discusses the submission of an environmental assessment report on perfluoroalkyl sulfonates, including PFOS, PFHS, and PFBS, related to the 3M Decatur, Alabama manufacturing site, as part of a voluntary environmental monitoring program following a Memorandum of Understanding with the EPA.
|
2008 |
AR226-3828
|
G5ZDx595qyey5djB0V0EyB10v |
2 |
|
The document is a submission to the TSCA 8(e)/FYI database regarding PFOA/PFOS, including C-8 Science Panel Status Reports and a study on health effects among residents exposed to perfluorooctanoate.
|
2008 |
AR226-3834
|
zQBywjRy2jdB56MRN4Gyq5RE0 |
1 |
|
The document outlines the C8 Science Panel's submission of three status reports to the Wood County Court regarding health studies on PFOA levels and their associations with health outcomes in a community exposed to perfluorinated compounds, specifically focusing on cholesterol, diabetes, and uric acid.
|
2008 |
AR226-3835
|
MJ6rk3G10Qyg5O7wwKb2eKazj |
14 |
|
A study evaluated the health status of 566 residents exposed to perfluorooctanoate (PFOA) in their drinking water, finding statistically significant higher prevalence rates of serious health issues such as angina, myocardial infarction, stroke, chronic bronchitis, and asthma, suggesting a potential link to PFOA exposure.
|
2008 |
AR226-3836
|
5Le8d5pLG3QM75dJ6zBLGzg30 |
15 |
|
The document is a TSCA 8(e) Substantial Risk Notice regarding PFOA, indicating that a final report will be forwarded to the EPA once available, highlighting potential risks associated with the substance.
|
2007 |
AR226-3829
|
VJ6KppLLXL2q9BEqK708Nb7Gg |
1 |
|
3M notified the EPA of a substantial risk regarding an experimental fluorinated surfactant salt, indicating it is a dermal sensitizer based on a mouse local lymph node assay that showed significant immune response changes.
|
2007 |
AR226-3830
|
JN055Q6q69KwjnZg6BmOJm27r |
1 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the US EPA regarding PFOA, indicating potential risks associated with the substance.
|
2007 |
AR226-3832
|
emEpQgLBRq85dV3X7qg78zoGe |
1 |
|
The document details a Local Lymph Node Assay (LLNA) study conducted by MB Research Laboratories on the test article MTDID 6675.1, sponsored by 3M Corporate Toxicology & Regulatory Services, to evaluate the skin sensitization potential of the compound in female CBA/J mice.
|
2007 |
AR226-3831
|
mBYBmEG2yYb8eaGnd3LmgbG90 |
57 |
|
The document discusses the results of a developmental toxicity screening study of the test article MID 6675 in rats, conducted by Charles River Laboratories, which involved administering various dosage levels of the test substance via oral gavage to evaluate its effects on presumed pregnant rats.
|
2007 |
AR226-3833
|
b5LBjXpB5G47k61nEzqGg0gRk |
123 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA reporting significant increases in liver and adrenal weights in male and female rats, respectively, following a 28-day oral gavage toxicity study on an experimental fluorinated surfactant salt.
|
2007 |
AR226-3837
|
jmpp1QpNgwZDzrgaQxn4Qq3rk |
1 |
|
This is a fax transmission from Robert A. Bilott, Esq. of Taft, Stettinius & Hollister LLP, dated June 10, 2002, sent to multiple recipients including various officials from the West Virginia Department of Environmental Protection and the U.S. Environmental Protection Agency.
|
2007 |
AR226-1098
|
65YzM6pZ655v5G6m6Zkqyw17m |
19 |
|
This document is a letter from Robert A. Bilott to Mary Dominiak of the EPA, submitting various documents related to PFOA for inclusion in Administrative Record 226, including critiques and press releases about C-8 levels in Ohio community water supplies.
|
2007 |
AR226-1155
|
RjJBKmp0aqXdnOvK2rk42yRBz |
2 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP regarding the submission of additional information to the IRIS Submission Desk related to Perfluorooctanoic Acid (PFOA) and its potential toxicological effects, referencing several scientific studies.
|
2007 |
AR226-1162
|
6wO6B48VkwwoYnmodJR1Oz8qo |
2 |
|
This is a letter from Taft, Stettinius & Hollister LLP, dated December 16, 2002, transmitting documents for inclusion in Administrative Record 226 related to environmental matters.
|
2007 |
AR226-1163
|
6BLyaRoKm1JMw3ya0mQ95odZE |
2 |
|
This document is a letter from Taft, Stettinius & Hollister LLP addressing the U.S. EPA regarding human health threats from releases of PFOA/APFO/C-8 in West Virginia and Ohio, serving as a supplement to a previous correspondence on the same topic.
|
2007 |
AR226-1307
|
5LmwL2qK3MaO2DKamGEw2LZQ5 |
3 |
|
The document is a letter from Robert A. Bilott to various EPA officials regarding a class action lawsuit against E.I. duPont de Nemours and Company for the contamination of drinking water with perfluorooctanoate (PFOA) in West Virginia and Ohio.
|
2007 |
AR226-1173
|
x5nYKzbpp1v18z92J8kB56e8J |
4 |
|
This document is a communication from the law firm representing plaintiffs in a lawsuit against E.I. duPont de Nemours and Company regarding issues related to PFOA.
|
2007 |
AR226-1175
|
RpZYzQ6mw28eQwV8aKmB212jE |
3 |
|
This letter discusses the West Virginia Department of Environmental Protection's decision not to independently verify the C-8 (PFOA) toxicity results obtained by DuPont's contractor, Exygen, and confirms the denial of a request to appoint a representative to the C-8 Assessment of Toxicity Team under a consent order.
|
2007 |
AR226-1178
|
x550KZ3gL2wd2K3NVQDY13p0J |
2 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP requesting permission to speak with EPA and ATSDR representatives regarding the C-8 (PFOA) Assessment of Toxicity Team's screening levels for C-8 established under a Consent Order with DuPont, highlighting the law firm's representation of plaintiffs in litigation against DuPont.
|
2007 |
AR226-1184
|
dQgvkMB9kM2XDGxVb9Zq75E9q |
2 |
|
This letter from Taft, Stettinius & Hollister LLP addresses document production issues with the West Virginia Department of Environmental Protection (WVDEP) related to outstanding requests, indicating that there may be recently-generated documents concerning PFOA that have not yet been produced.
|
2007 |
AR226-1185
|
g2XkO2rk5RXgkemLYbL6zK49 |
18 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP regarding a class action lawsuit against E.I. duPont de Nemours and Company for allegedly releasing ammonium perfluorooctanoate (C-8) into the environment from its Washington Works facility in Wood County, West Virginia.
|
2007 |
AR226-1189
|
rpNmZZ0DD8MkajZe34mK5gzRe |
120 |
|
The document is a notification letter from Taft, Stettinius & Hollister LLP regarding a human health threat arising from releases of PFOA/APFO/C-8 in West Virginia and Ohio, addressed to various officials at the U.S. Environmental Protection Agency.
|
2007 |
AR226-1216
|
2qvj3eNGBnkJRZ3jgbanwOa7R |
60 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, submitting various reports related to PFOA monitoring and assessments from DuPont and other sources for inclusion in Administrative Record 226.
|
2007 |
AR226-1232
|
XOLDDwN4NJxLe20woZbaBj74d |
2 |
|
This document is a letter from Taft, Stettinius & Hollister LLP to the EPA, submitting various reports related to the effects of PFOA contamination in the Dry Run Creek area of Wood County, West Virginia, for inclusion in Administrative Record 226.
|
2007 |
AR226-1239
|
1DBjnEB04Z6enLga1mkYEr55 |
2 |
|
This letter from Taft, Stettinius & Hollister LLP to the EPA provides supplemental information regarding E.I. duPont de Nemours and Company's knowledge of health effects related to exposure to ammonium perfluorooctanoate (PFOA) and its implications for public health and safety.
|
2007 |
AR226-1441
|
j2364meYzQO1Lb4MqzmXM5nO |
11 |
|
The document is a communication from Taft, Stettinius & Hollister LLP to the EPA regarding DuPont's reporting under TSCA Section 8(e) about PFOA, specifically addressing findings related to eye defects in cattle exposed to contaminated water.
|
2007 |
AR226-1472
|
q379OGONvokM07Jy9pkOyp5K5 |
2 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, submitting additional copies of previously included documents related to PFOA for Administrative Record 226, following DuPont's confidentiality claims.
|
2007 |
AR226-1244
|
mVnN4L2DXkRkr7zM3bLpmw1k |
1 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA regarding the human health threat posed by PFOA releases from the DuPont Washington Works Plant in West Virginia, providing supplemental information on the health evaluations of workers exposed to PFOA.
|
2007 |
AR226-1544
|
da8KVrB7N8Gb8zg7RDExdLoE6 |
2 |
|
This document is a letter from Taft, Stettinius & Hollister LLP to the EPA, providing additional information regarding E.I. duPont de Nemours and Company's knowledge of health effects related to exposure to ammonium perfluorooctanoate (PFOA) at the time they obtained pregnancy outcome and drinking water contamination data.
|
2007 |
AR226-1554
|
3JdgMGLLJ0m6r10aJLp7MM96J |
8 |
|
This document is a correspondence from Robert A. Bilott to the EPA regarding the submission of DuPont documents related to the presence of PFOA in various production processes and products, highlighting concerns about its potential threat to human health and the environment.
|
2007 |
AR226-1645
|
R8QLo5B8Gg0M1nBX5BOwkvvv |
3 |
|
This document is a letter from Taft, Stettinius & Hollister LLP to the EPA regarding DuPont's reporting of PFOA drinking water contamination data under TSCA, including additional documents and emails that discuss the involvement of DuPont and 3M's counsel in the preparation of a report proposing a safety level for PFOA in drinking water.
|
2007 |
AR226-1675
|
GK32950mkE32KXqMeZpO014y7 |
2 |
|
The document is a laboratory report from 3M detailing the determination of the presence and concentration of Potassium Perfluorooctanesulfonate (PFOS) in the serum and liver of Sprague-Dawley rats exposed to PFOS via gavage, initiated on May 26, 1998.
|
2006 |
AR226-0560
|
2qjQGv9b4Vp0Ed4BY7oYym3Mp |
23 |
|
This document is a report from CXR Biosciences detailing a 13-week study sponsored by 3M to investigate the reversibility of effects induced by perfluorooctane sulfonate (PFOS) in male Sprague Dawley rats.
|
2006 |
AR226-3822
|
MGjqBaZOGLBzNOnoj6on26Y7y |
139 |
|
3M submitted a supplemental report to the EPA detailing a pharmacokinetic study that found perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS) in rats, with peak PFOS concentrations observed in the liver on day 4 post-dose.
|
2004 |
AR226-1694
|
0LgKpvk3o48ZxonVeo3LqREXb |
1 |
|
This correspondence from 3M to the EPA discusses the submission of additional background information related to monitoring programs for perfluorinated chemicals, including a CD on wildlife sample analysis and details on a market basket survey concerning PFOS and PFOA.
|
2004 |
AR226-1696
|
XZbZvGwvYyOLkNR3o7Q6x4d |
2 |
|
The document is a final report from 3M's Strategic Toxicology Laboratory detailing a pharmacokinetic study that found perfluorooctanesulfonyl fluoride (POSF) is metabolized to perfluorooctanesulfonate (PFOS) in rats, with maximum PFOS concentration observed in the liver on day 4 post-dose.
|
2004 |
AR226-1695
|
3yE9vp7OgGaV0nNRv2KZNkd3 |
11 |
|
The document is a correspondence from Daikin America to the EPA, submitting detailed analytical reports related to PFOA in soil and groundwater at their Decatur facility, as requested by the agency.
|
2004 |
AR226-1702
|
LD173onjjVbEJLa9KrZv2bkQ |
2 |
|
Daikin America, Inc. submitted surface water testing analytical reports to the EPA, revealing PFOA concentrations in wastewater and sludge samples from their Decatur, Alabama facility, with results ranging from 0.282 to 1.8 ng/mL in wastewater and 9.3 to 48.73 µg/g in sludge.
|
2004 |
AR226-1707
|
1049LQ330nq6mRgGjyYNVEoxq |
3 |
|
The document is a correspondence from Taft, Stettinius & Hollister LLP regarding a PFOA human health effects study, specifically addressing cancer data related to the substance.
|
2004 |
AR226-1714
|
3eqw13b3LyZDDd04KMm7kQnyn |
1 |
|
The document discusses a study by James Dahlgren that found elevated cancer prevalence rates among residents exposed to PFOA from a Dupont manufacturing plant, indicating higher rates of prostate, cervix, and uterine cancers compared to the general population and highlighting differences in cancer distribution between residents and PFOA-exposed workers.
|
2004 |
AR226-1715
|
YrZ6L28apVKyBXbkLJ4rEkRJK |
2 |
|
3M is submitting updated data and studies on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA, including revised reports on the Tennessee River study and addenda correcting reported values in PFOS ecotoxicological studies due to new analyses of sample purity.
|
2004 |
AR226-1717
|
3NMerwOYo93Qd8BEMr4VRxxrJ |
8 |
|
This is a bibliography of published literature related to perfluorinated compounds, including studies on perfluorooctanoic acid and its environmental impacts.
|
2004 |
AR226-1718
|
E3xrKm7JQXKNEDEG3vVZY3Zx |
5 |
|
The document is a final report on a study evaluating the metabolism and toxicological effects of perfluorooctanesulfonamide (FOSA) in male rats, specifically focusing on hepatic peroxisome proliferation after administering a dose of 40 mg/kg/day for four consecutive days.
|
2004 |
AR226-1731
|
mp7Q2k5oJ85nyQ9OnObNxDv7k |
18 |
|
3M submitted a supplemental report to the EPA regarding a pharmacokinetic study on ammonium perfluorooctanoate (PFOA) in rats, following previous communications about related reproductive studies.
|
2004 |
AR226-1550
|
NGx7p9Yo8yKEnZQp9dDB2pe98 |
1 |
|
3M submitted a supplemental report to the EPA detailing the results of a study on ammonium perfluorooctanoate (PFOA) that examines the age effect on plasma concentration in post-weaning rats following oral gavage.
|
2004 |
AR226-1552
|
o9aE40oaJ5D5Bea4b6Byky293 |
1 |
|
DuPont submitted three abstracts related to perfluorinated compounds, authored by James Dahlgren for plaintiffs in a class action lawsuit, to the EPA for informational purposes, clarifying that the abstracts do not indicate any actual risk or meet reporting criteria under TSCA Section 8(e).
|
2004 |
AR226-1770
|
MG1OgX2QxpLd92vNxZNqzy44y |
4 |
|
DuPont submitted air monitoring data related to PFOA from its Washington Works facility to the EPA as part of an Air Modeling Verification Study, including preliminary results and analytical reports on particle size distribution.
|
2004 |
AR226-1774
|
ymdj5B05p9pVg0kXOoRXL0wm4 |
3 |
|
This document summarizes intermediate results from the Air Modeling Verification Study related to PFOA air monitoring at the DuPont Washington Works site, detailing initial comparisons between monitored ambient air measurements and air dispersion modeling results.
|
2004 |
AR226-1775
|
KzJ4rJ4mKj34d4a3oYmqK9YBX |
4 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA regarding the PFOA Environmental Monitoring/Sampling Information, providing additional documents related to environmental modeling and sampling for PFOA conducted by DuPont at various facilities.
|
2004 |
AR226-1669
|
zQ4yJpqwaLoOR6x2nvp4pxkd0 |
2 |
|
This analytical report from Centre Analytical Laboratories details the characterization of water and sediment samples collected from Port St. Lucie, Florida, for 3M Project E00-2003, specifically analyzing for perfluorooctane sulfonate (PFOS), perfluorooctane sulfonamide (PFOSA), and perfluorooctanoate (POAA) using liquid chromatography
|
2003 |
AR226-0676
|
Emx8M3BkDk38mErkpJrD2oa7R |
9 |
|
The document is a letter from DuPont's Stephen H. Korzeniowski to EPA's Mary Dominiak, submitting information about the Telomer manufacturing process related to the potential release of PFOA as part of the Telomer Research Program's voluntary commitment.
|
2003 |
AR226-1265
|
MJzpKMp4KGqXgzd0d4BKDxd5k |
1 |
|
The document outlines the Telomer Research Program, detailing the manufacturing processes for telomer-based fluorochemicals, specifically noting that PFOA is not used or added in these processes and that emissions are expected to be very low.
|
2003 |
AR226-1266
|
7MqMYvzzJL27znRyemqjyG2qa |
6 |
|
Dyneon LLC submitted a letter to the EPA detailing their compliance with the PFOA Users Letter of Intent by providing a list of their manufacturing site in Decatur, Alabama, where they produce fluoropolymers using APFO (CAS No. 3825-26-1).
|
2003 |
AR226-1270
|
nmRGVzn1YNQgdwkn2eq6XZEdw |
1 |
|
The document is a communication from Katie D. Smythe of the Telomer Research Program to Mary F. Dominiak at the EPA, providing draft study plans for analyzing PFOA in telomer-based products and treated articles, and requesting feedback by February 28.
|
2003 |
AR226-1271
|
k9Dk59VxbJ2x4g48RKxNVEejn |
1 |
|
The document outlines a proposed study plan for analyzing PFOA levels in 11 different telomer-based products using LC/MS/MS methodology, with the aim of determining the presence and concentration of PFOA by May 2003.
|
2003 |
AR226-1272
|
kDjnZwxzD644JaYOa9XBZ9rRJ |
2 |
|
The document outlines a proposed study plan for analyzing PFOA levels in 11 articles treated with telomer-based products, using LC/MS/MS methodology to determine the presence and concentration of PFOA, with analyses to be completed by May 2003.
|
2003 |
AR226-1273
|
emjNGwQG41LXR2vx0QDmqQYXm |
4 |
|
The document outlines a preliminary study for the Telomer Research Program, detailing the sampling and analysis procedures for extracting PFOA from treated and untreated carpet and textile matrices at various concentrations.
|
2003 |
AR226-1274
|
g2ZRJQNxMjw5V95ovJ8kYLjde |
5 |
|
The document is a submission of the final study report on perfluorinated compounds to the EPA's AR-226 administrative record, specifically addressing findings related to the Telomer Research Program.
|
2003 |
AR226-1275
|
JrapzDNdVaomjaj68kE093aL2 |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the U.S. EPA, providing two journal articles for inclusion in Administrative Record 226, which focus on environmental levels of PFOS in Japan and blood levels of PFOA in Japanese individuals.
|
2003 |
AR226-1277
|
8RR7n5xzMM3znpEr5NR8Qbz0a |
1 |
|
This document discusses the first environmental survey of perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in Japan, highlighting their global distribution, environmental persistence, bioaccumulation, and the need for further investigation into their toxicity and environmental impact.
|
2003 |
AR226-1278
|
pmVk6KYD7DxqkYk2aReZjD4Z7 |
4 |
|
This document is a progress report submitted by Katie Smythe on behalf of the Telomer Research Program to the U.S. EPA, detailing Year 1 findings from the University of Toronto's research on fluorotelomer alcohols, with no confidential business information included.
|
2003 |
AR226-1280
|
wgqKwROVx6Q640494x1kL4gNJ |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the EPA, detailing the scope and rationale for the "8-2 Telomer B Alcohol Biodegradation Research" as part of ongoing TRP research activities.
|
2003 |
AR226-1282
|
938VOzQ1Od09LbqKDN552rqRD |
1 |
|
The document is a submission from the Telomer Research Program to the EPA, detailing the scope and rationale for a study on "Analysis of Telomer-Based Products and Telomer-Treated Articles," which is part of their voluntary commitment regarding perfluorinated compounds.
|
2003 |
AR226-1284
|
wgbeOb73aXOzYX6XQvQJoR03 |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program to the EPA, providing study reports on 8-2 Telomer B Alcohol (CAS# 678-39-7) for inclusion in Administrative Record 226, confirming that none of the attached files contain Confidential Business Information.
|
2003 |
AR226-1286
|
375ozQY7G6yMNd0rqgG9r87qO |
1 |
|
The document outlines the Telomer Research Program's investigation into the potential release of perfluorooctanoic acid (PFOA) from telomer-based products and treated consumer articles, focusing on analyzing PFOA levels in carpets, textiles, and paper to assess human and environmental exposure.
|
2003 |
AR226-1285
|
BpLwkn1v0VX4JKZZN0gw09Do |
4 |
|
The document is a DuPont report detailing the vapor pressure determination of 8-2 Telomer B Alcohol (C8F17CH2CH2OH), conducted under the Telomer Research Program, with the study completed on July 16, 2002, and reported on March 21, 2003.
|
2003 |
AR226-1288
|
wr9D3X7n6BMopeyYJN72GeRNQ |
10 |
|
The document is a submission from the Telomer Research Program to the EPA, providing a list of documents related to telomers, including studies on physical-chemical properties, toxicology, and environmental effects, with a commitment to submit the actual documents by April 15, 2003.
|
2003 |
AR226-1291
|
Rpe4VwojO4XgddGke5nK71zeB |
1 |
|
This document appears to be a summary of available data types related to various perfluoroalkyl substances (PFAS) analyzed under the Telomer Research Program, detailing their physical properties, toxicity, and environmental effects.
|
2003 |
AR226-1292
|
XRB6z68VLZXJOEbyOOK4oJ3gR |
2 |
|
DuPont submitted a letter to the EPA detailing its U.S. sites that use Ammonium Perfluorooctanoate (APFO) to produce fluoropolymers, as part of its commitment following a voluntary action letter dated March 14, 2003.
|
2003 |
AR226-1295
|
omXbNbk0YYB0w2BpXzOjXQOM3 |
2 |
|
This document is a presentation from the Telomer Research Program meeting held on February 3, 2003, detailing information sharing and study reports related to telomer manufacturing and environmental impacts, prepared for the U.S. EPA's OPPT.
|
2003 |
AR226-1299
|
aJ11gqj2pZG3OYo9gOr2GdKrM |
25 |
|
3M Company outlines its ongoing environmental, health, and safety measures regarding perfluorooctanoic acid (PFOA), including past efforts to characterize exposure, conduct research, and plans for future monitoring and data development related to PFOA exposure from its former manufacturing activities.
|
2003 |
AR226-1303
|
6YE2Gd1dj9YO6eGG6XZV4QE6 |
9 |
|
The document is a Letter of Intent from several companies, including Asahi Glass Fluoropolymers USA, Daikin America, and E. I. du Pont de Nemours, to the EPA, outlining their initiatives to assist in the assessment of ammonium perfluorooctanoate (APFO) and ensure its safe use in the manufacture of fluoropolymers.
|
2003 |
AR226-1304
|
5k8Y06axk4DgLLrEbQaoEL7NJ |
26 |
|
The document is a Letter of Intent from members of the Telomer Research Program to the EPA, outlining their commitment to address concerns regarding the potential association of perfluorooctanoic acid (PFOA) with telomer-based products and detailing their evaluation of PFOA exposure from these products.
|
2003 |
AR226-1305
|
pzzy13brwrM49aEk9vnODdod |
20 |
|
This letter reaffirms the commitment of several companies, including DuPont and Daikin America, to assist the EPA in investigating perfluorooctanoic acid (PFOA) and ammonium perfluorooctanoate (APFO), focusing on developing data regarding their health and environmental effects and improving exposure prevention measures.
|
2003 |
AR226-1306
|
4QQZdXLbgmLxg5qX1jLw35Vee |
10 |
|
The document is a report from the Epidemiology Program detailing cancer incidence data from 1959 to 2001 at the DuPont Washington Works site in Parkersburg, West Virginia, comparing observed cancer cases to expected cases using the Standardized Incidence Ratio (SIR).
|
2003 |
AR226-1307
|
Lp2yJJV9Zavo2GGeB6kZDGBeb |
19 |
|
This document is a letter addressing the potential human health threat from releases of PFOA (C-8) from the E.I. duPont de Nemours and Company plant in West Virginia and Ohio, sent to various officials at the U.S. Environmental Protection Agency and the Ohio Environmental Protection Agency.
|
2003 |
AR226-1308
|
x5g4NeXj1wDd1XGra1do447zQ |
2 |
|
The memorandum summarizes a March 5, 2003 meeting between EPA and representatives from 3M, DuPont, and Daikin to discuss perfluorooctanoic acid (PFOA), where industry representatives expressed their views on PFOA risks and outlined their voluntary product stewardship efforts, including commitments to reduce emissions and assess environmental presence.
|
2003 |
AR226-1309
|
ZJoQEpXbXdxJvyvqqmKwD55aY |
2 |
|
The memorandum summarizes a March 14, 2003 meeting between EPA officials and the Environmental Working Group, where concerns were raised about the hazards, exposures, and risks associated with PFOA and PFOS, including their widespread presence in humans and the environment, as well as the potential for telomer alcohols to biodegrade into PFOA.
|
2003 |
AR226-1310
|
KJ4O0ZYY4j2vvLKLOdz9evB36 |
1 |
|
The memorandum discusses the Preliminary Risk Assessment of the developmental toxicity associated with PFOA (Perfluorooctanoic Acid) and its salts, highlighting the use of human and rat serum data for calculating margins of exposure (MOEs) and acknowledging limitations in the available data.
|
2003 |
AR226-1311
|
evxgBQQoy44MVGx9XEoEkx90e |
4 |
|
The document is a submission to the EPA's AR 226 regarding the mechanics of film formation of aqueous film-forming foam (AFFF) fire fighting agents, including attached presentations and papers on fluorosurfactants, in response to an EPA request for information.
|
2003 |
AR226-1312
|
qknDxDzXoKbn1ReMJVOraN8Yk |
1 |
|
The document discusses the properties and effectiveness of fluorinated surfactants, specifically in the context of fire fighting foams, highlighting their thermal and chemical stability, as well as their unique surfactant characteristics due to the perfluorinated chain structure, authored by Martial Pabon from DuPont.
|
2003 |
AR226-1313
|
8598LyoLO6RmOJ26p7335vK8Z |
19 |
|
This is a letterhead cover page from DuPont, with no analytical content retained in the OCR.
|
2003 |
AR226-1316
|
k65dRD75KeeoyDn1ea34yM68O |
1 |
|
The document is a submission from DuPont detailing the 2002 sales and usage data of their telomer-based products in the United States, which includes information on various applications such as carpet, coatings, and firefighting foam, as part of their commitment to the EPA's Telomer Research Program.
|
2003 |
AR226-1317
|
vBomgRQgbOQErdYbL6mBqEr2Y |
2 |
|
3M submitted a supplemental report to the EPA detailing ecotoxicity studies on triphenylbenzyl phosphonium cation/N-methyl perfluorooctanesulfonamide salt (TPBP C8 amide), indicating acute toxicity to zebra-fish, Daphnia magna, and algae, while asserting that environmental exposure is unlikely due to its use in fluoroelastomer production.
|
2003 |
AR226-1319
|
9154Zd4o0oN740Vevro8VwEN5 |
2 |
|
The document is a letter from the EPA to DuPont regarding TSCA 8(e) reporting requirements for PFOA, highlighting concerns raised by an Environmental Working Group report about PFOA exposure among female workers and related health effects, including findings of PFOA in umbilical cord blood and potential birth defects.
|
2003 |
AR226-1318
|
M4G8B2YvrdKr7K23KVdkwpXM |
6 |
|
3M submitted a substantial risk notice to the EPA regarding an acute eye irritation study on phosphonium, triphenyl(phenylmethyl)-, salt with 1,1,2,2,3,3,4,4,4-nonafluoro-N-methyl-l-butanesulfonamide (CAS 332350-93-3), which indicated ocular corrosion and nec
|
2003 |
AR226-1322
|
a4RbwzvGbXkaQ7Gk4XGbzkr0a |
2 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding the fluorochemical alcohol 1-butanesulfonamide, 1,1,2,2,3,3,4,4,4-nonafluoro-N-(2-hydroxyethyl)-N-methyl (CAS 34454-97-2), indicating that a subchronic oral
|
2003 |
AR226-1324
|
EqvZaYryvMaY6YGm5v7NggyVx |
2 |
|
This letter from DuPont's Corporate Counsel addresses the EPA's inquiry regarding the reportability of PFOA-related health and environmental data under TSCA Section 8(e), asserting that the information does not indicate a "substantial risk" and therefore does not require reporting.
|
2003 |
AR226-1327
|
OJzvqnZ1N9omN6RNpKk1koLXL |
10 |
|
This document is a submission from 3M to the EPA regarding the final reports of three ecotoxicity studies on triphenylbenzyl phosphonium cation/N-methyl perfluorooctanesulfonamide salt (TPBP C8 amide), indicating that the results are consistent with previously reported information.
|
2003 |
AR226-1334
|
44ZpxEX5B4nGvBGDYLBoKkqDR |
1 |
|
This is a document submission cover letter from Katie Smythe on behalf of the Telonrer Research Program, indicating the submission of materials related to the TRP.
|
2003 |
AR226-1338
|
5K3Lxr4DN511rj73NLv7v4nJ |
1 |
|
Asahi Glass Co., Ltd. submitted information to the EPA regarding their telomer-based products, including both polymeric and non-polymeric types, as part of their regulatory compliance efforts for products exported to the United States.
|
2003 |
AR226-1326
|
npndmo1gLXvbrwMLovxqgLDq6 |
2 |
|
This is a document submission from the Telomer Research Program, prepared by Katie Smythe, regarding unspecified analytical content.
|
2003 |
AR226-1343
|
3JB1d8qB6D75B6wwvrmnKdXmD |
1 |
|
The document reports on a study conducted by DuPont on the acute oral toxicity of 8-2 Telomer B Alcohol, indicating no clinical signs of toxicity were observed at the tested doses.
|
2003 |
AR226-1344
|
Ozapq538gXB3NwDwZopypaJ5L |
1 |